Navigation Links
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
Date:12/9/2012

ells to either die immediately or undergo maturation (and eventually die). This eliminates enough leukemia cells to make it possible for patients to undergo stem cell transplants that can cure their disease.

In order to assess the efficacy and safety of quizartinib as a single agent (drug used alone in treatment) in AML patients with the FLT3-ITD mutation, researchers conducted a Phase II study among 333 patients that were divided into two treatment cohorts. Cohort 1 consisted of patients age 60 or over with the FLT3-ITD mutation who failed to achieve remission with standard chemotherapy, or who had recently relapsed for the first time. Cohort 2 consisted of patients over age 18 with the FLT3-ITD mutation who presented with relapsed or refractory AML and had been administered salvage chemotherapy after failing to respond to prior treatment, or had relapsed after a stem cell transplant. Most patients in this study had the FLT3-ITD mutation, but a small number in each cohort lacked the mutation.

Study results from Cohort 2 were based on an analysis of 137 patients (99 with mutation and 38 without) who received continuous treatment with quizartinib at a fixed dose during 28-day cycles. The primary endpoint of the study was the composite complete remission rate (CRc) of all patients, which includes complete remission (CR; no active disease), complete remission with incomplete platelet recovery (CRp, no active disease but abnormal platelet count), and complete remission with incomplete hematologic recovery (Cri, no active disease but abnormal red and white blood cell counts) of the patients following treatment with quizartinib.

Following one to three cycles of quizartinib treatment, researchers observed a CRc rate of 44 percent (4% CR, 0 CRp, and 40% CRi) in patients with the FLT3-ITD mutation with a median duration of response of 11.3 weeks and median overall survival of 23.1 weeks. In patients without the mutation, researchers observed a 34
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Researchers develop novel 3-D culture system for inflammatory breast cancer
2. ACNP: Novel NMDA receptor modulator significantly reduces depression scores within hours
3. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
4. Novel mechanism through which normal stromal cells become cancer-promoting cells identified
5. Novel breast screening technology increases diagnostic accuracy
6. UNC, Vanderbilt discover a new live vaccine approach for SARS and novel coronaviruses
7. Moffitt Cancer Center researchers identify novel metabolic programs driving aggressive brain tumors
8. Novel treatment strategies for epilepsy
9. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
10. Researchers ID potential patient population who may benefit from novel anti-platelet treatment
11. Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
(Date:10/1/2014)... 01, 2014 Bedros Keuilian is not ... Camp fitness boot camps, he’s also considered the leading ... with sold out business summits, a line of high-demand ... to a recent Spike TV reality show to his ... is the time for personal trainers and fitness business ...
(Date:10/1/2014)... Conn. (PRWEB) October 01, 2014 ... company, including a redefined mission and visual identity ... power of partnering with them to create greater ... agile brand that focuses on empowering customers to ... communications. , The crown jewel of the rebrand ...
(Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
(Date:10/1/2014)... On Sept. 9, Chapín Coffee was selected as ... American Made Awards (MSAMAs), an annual competition in recognition ... fields of crafts, design, food and style. , ... the MSAMAs, which celebrates entrepreneurs and artisans who are ... and changing the way we shop, work and live,” ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:Chicago Coffee Start-up Makes a Big Impact, Earns National Recognition 2
... Italy, September 21 Health Robotics today,announced that ... Device Technologies Australia Pty Ltd. for its revolutionary,CytoCare(TM) ... achieve its goal of safely, accurately and cost-effectively,automating ... its,other market-leading Oncology and Surgery Robotic solutions. , ...
... Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce ... its MammoView(TM) line of surgical endoscopy instruments from approximately 30 ... the last 12 months. More than half of the purchase ... and private Universities across the Country. , , ...
... , , KANSAS CITY, Mo., Sept. ... and Prevention (CDC), recommend seasonal influenza vaccination as the first line ... , The American Lung Association of the Central ... initiative in Kansas City and is supporting local public health efforts ...
... ST. LOUIS, Sept. 21 KV ... (Nasdaq: PRGO ) of KV,s first-to-file Paragraph IV Abbreviated ... for a generic equivalent version of GlaxoSmithKline,s Duac(R) gel. , ... will receive $14 million from Perrigo at closing and an additional, ...
... , , , Sponsored by ... , WEST CONSHOHOCKEN, Pa., Sept. 21 Austin Retina Associates ... SupportSight seminar in Austin on October 3rd. SupportSight ... macular degeneration and for those who would like to learn more about ...
... , , FRANKLIN, Mass., Sept. ... company focused on innovative cardiac and vascular medical device-based technologies, ... Transcatheter Cardiovascular Therapeutics (TCT) 2009, sponsored by the Cardiovascular Research ... More than 11,000 clinicians and professionals are expected to ...
Cached Medicine News:Health News:Health Robotics Continues Global Expansion Into Oceania With Device Technologies Australia's Strategic Partnership 2Health News:Health Robotics Continues Global Expansion Into Oceania With Device Technologies Australia's Strategic Partnership 3Health News:Solos Endoscopy, Inc.'s MammoView(TM) Product Line Receives New Purchase Orders Primarily from Prestigious Teaching Hospitals Across the Country 2Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 2Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 3Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 4Health News:The American Lung Association of the Central States Encourages Greater Kansas City Metro Residents to See Themselves Among the Many 'Faces' of Influenza 5Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 2Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 3Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 4Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 5Health News:KV Pharmaceutical Divests ANDA for Generic Version of Duac(R) 6Health News:SupportSight Comes to Austin, Saturday October 3 - Free Seminar for Those Affected by Macular Degeneration 2Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at TCT 2009, Building on Success at ESC 2009 2Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at TCT 2009, Building on Success at ESC 2009 3Health News:PLC Medical Systems to Demonstrate RenalGuard(R) at TCT 2009, Building on Success at ESC 2009 4
(Date:10/1/2014)... and NOTTINGHAM, England , Oct. 1, ... ) today announced that its subsidiary, Molecular Profiles Ltd., ... platform at the annual CPhI/ICSE Worldwide event in ... support companies with the rapid development of both standard ... technologies screening platform, which incorporates the company,s existing formulation ...
(Date:10/1/2014)... , Oct. 1, 2014  Varian Medical Systems ... will report results for the fourth quarter of fiscal ... Wednesday, October 22, 2014.  The news release will be ... at 2:00 p.m. PT.  The news release and a ... on the company website at: www.varian.com/investor .  To ...
(Date:10/1/2014)... , Oct. 1, 2014  SI-BONE, Inc., a medical device ... ® a minimally invasive surgical (MIS) device indicated for ... announced the expansion of its European operations with the formation ... Schaber as General Manager, Germany.  Mr. Schaber will join ... of Europe , Middle East ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4
... Md., April 26, 2012 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... providing health care services in China through the operations ... care hospitals and affiliated ambulatory clinics, today announced that ... first quarter of 2012 ended March 31, 2012 on ...
... 2012 Medical sales recruitment specialists Advance ... new global medical device survey for 2012-2013 suggesting a ... climate. The report, which was published this ... a highly detailed analysis drawn from ICD research,s panel ...
Cached Medicine Technology:Chindex International, Inc. to Report First Quarter 2012 Financial Results 2Advance Recruitment Delighted With Positive Outlook for Medical Device Sales Industry 2
Improve your refractive outcome, with AXIS II precision biometry A-scan. Biometry clinically proven as accurate as partial coherence interferometry while not limited by dense media....
... with graphic display and IOL power ... combination units include firmware module with ... II formulas. Audible tones increase in ... visual axis. Constant tone when alignment ...
... ("I-cubed") is an exceptionally high resolution, ... oscilloscope (static deflection) display. This provides ... low cost video monitors. Vitreous structures ... cells, as well as tumor vascularity ...
... sensitive B-scan system which quickly identifies ocular asymmetry. ... eyes differ by more than 0.3 mm, a ... The B5500 enables quick and easy identification of ... or inserting shells under the lids. The B5500 ...
Medicine Products: